1144. Rate of Infusion Reactions Among Patients Receiving Casirivimab/Imdevimab in the Home Setting
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac492.982
Abstract: Abstract Background Monoclonal antibodies used in the treatment and prevention of COVID 19 infection are an emerging area of infectious disease. Casirivimab/imdevimab received emergency use authorization (EUA) for the prophylaxis and treatment of COVID 19… read more here.
Keywords: infusion reactions; infusion time; casirivimab imdevimab; rate ... See more keywords
Effect of montelukast and rupatadine on rituximab infusion time, rate, severity of reactions, and cost of administration.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.6500
Abstract: 6500 Background: Rituximab is associated with frequent infusion reactions which carry significant burden to patients and health care practitioners. Standard pre-medications (SP) do not prevent reactions sufficiently. Rupatidine (R) and Montelukast (M) are used for… read more here.
Keywords: infusion; rituximab; rate severity; infusion time ... See more keywords